Small Biotechs, Big Decisions is a limited podcast series exploring the challenges and opportunities facing emerging biotech companies today.
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Other ways to listen:
Daniel Chancellor
VP of Thought Leadership
View profile
VP of Thought Leadership
Norstella
Daniel has nearly 20 years of experience spanning drug development, market analysis, consulting, and pharmaceutical strategy. This gives him a broad view of what is required to bring therapies to market and where important operational and strategic pain points occur. His focus is on applying AI where it creates genuine value rather than introducing additional technology or complexity.
What makes Norstella's AI different?
The differentiator is the breadth of the underlying pharmaceutical dataset. Norstella can connect information from across the pipeline-to-patient journey, creating insights that would be difficult to generate from isolated datasets. AI extends the value that can be derived from that information.
What can pharma teams do now that was not possible two years ago?
One major advance is the ability to understand how patients appear in real-world healthcare and translate this into more effective targeting. AI can help bridge the gap between the controlled environment of a clinical trial and the much less structured reality of patient treatment.
How can AI accelerate the journey from pipeline to patient?
Trial design, portfolio investment, and market access decisions all consume substantial time. AI can help organizations make these decisions using a broader evidence base and do so more quickly, supporting faster development and potentially wider access to successful therapies.
